Inhibition of brain ST8SiaIII sialyltransferase leads to impairment of procedural memory in mice

Sialylated glycoproteins and sialyltransferases in digestive cancers: Mechanisms, diagnostic biomarkers, and therapeutic targets

Sialic acid (SA), as the ultimate epitope of polysaccharides, can act as a cap at the end of polysaccharide chains to prevent their overextension. Sialylation is the enzymatic process of transferring SA residues onto polysaccharides and is catalyzed by a group of enzymes known as sialyltransferases (SiaTs). It is noteworthy that the sialylation level of glycoproteins is significantly altered when digestive cancer occurs. And this alteration exhibits a close correlation with the progression of these cancers. In this review, from the perspective of altered SiaTs expression levels and changed glycoprotein sialylation patterns, we summarize the pathogenesis of gastric cancer (GC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and hepatocellular carcinoma (HCC). Furthermore, we propose potential early diagnostic biomarkers and prognostic indicators for different digestive cancers. Finally, we summarize the therapeutic value of sialylation in digestive system cancers.

Sialidase and Sialyltransferase Inhibitors: Targeting Pathogenicity and Disease

Sialidases (SAs) and sialyltransferases (STs), the enzymes responsible for removing and adding sialic acid to other glycans, play essential roles in viruses, bacteria, parasites, and humans. Sialic acid is often the terminal sugar on glycans protruding from the cell surface in humans and is an important component for recognition and cell function. Pathogens have evolved to exploit this and use sialic acid to either “cloak” themselves, ensuring they remain undetected, or as a mechanism to enable release of virus progeny. The development of inhibitors against SAs and STs therefore provides the opportunity to target a range of diseases. Inhibitors targeting viral, bacterial, or parasitic enzymes can directly target their pathogenicity in humans. Excellent examples of this can be found with the anti-influenza drugs Zanamivir (Relenza™, GlaxoSmithKline) and Oseltamivir (Tamiflu™, Roche and Gilead), which have been used in the clinic for over two decades. However, the development of resistance against these drugs means there is an ongoing need for novel potent and specific inhibitors. Humans possess 20 STs and four SAs that play essential roles in cellular function, but have also been implicated in cancer progression, as glycans on many cancer cells are found to be hyper-sialylated. Whilst much remains unknown about how STs function in relation to disease, it is clear that specific inhibitors of them can serve both as tools to gain a better understanding of their activity and form the basis for development of anti-cancer drugs. Here we review the recent developments in the design of SA and ST inhibitors against pathogens and humans.

Effects of milk fat globule membrane and its various components on neurologic development in a postnatal growth restriction rat model

BACKGROUND

Milk fat globule membrane (MFGM) is a component of breast milk that consists of glycosylated membrane-bound proteins, polar lipids and carbohydrates originating from the mammary gland plasma membrane. A commercially available bovine MFGM added to infant formula has been shown to improve cognitive development in infants at 12 months of age.

OBJECTIVE

Considering that MFGM is a complex mixture, our aim was to determine which component(s) may be leading to these cognitive outcomes.

METHODS

Growth-restricted rat pups were supplemented with one of five treatments: (a) bovine MFGM, (b) bovine phospholipid concentrate (PL), (c) sialic acid (SIA) at 200 mg/kg body weight (bw) SIA100, (d) SIA at 2 mg/kg bw and (e) nonfat milk as control. Pups were randomized, cross-fostered into litters of 17 pups per dam and supplemented from postnatal day (PD) 2 to PD 21. The following behavioral tests were performed at adulthood: T-Maze Spontaneous Alternation, Novel Object Recognition and Morris Water Maze. Hippocampus was isolated at PD14 and PD21. Expression of four genes were measured including brain-derived neurotrophic factor (BDNF), dopamine receptor 1, (Drd1), glutamate receptor (GluR-1) and ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialytransferase 4 (St8Sia4). Following behavioral testing, brains were collected for nonbiased stereology.

RESULTS

Increased expression of genes due to supplementation was most pronounced at the PD14 time point. The MFGM group exhibited higher T-Maze scores compared to the SIA group (P=.01), whereas the SIA100 group visited the novel object more frequently than the MFGM group in the Novel Object test (P=.02). No differences due to supplementation were found in the Morris Water Maze or nonbiased stereology, CONCLUSIONS: In this trial, MFGM, compared to its individual components, had the largest impact on neurodevelopment in rat pups through up-regulation of genes and improved T-Maze scores compared to the SIA group.

Sialic Acids in Neurology

Sialic acid (Sia) is involved in many biological activities and commonly occurs as a monosialyl residue at the nonreducing terminal end of glycoconjugates. The loss of activity of UDP-GlcNAc2-epimerase/ManNAc kinase, which is a key enzyme in Sia biosynthesis, is lethal to the embryo, which clearly indicates the importance of Sia in embryogenesis. Occasionally, oligo/polymeric Sia structures such as disialic acid (diSia), oligosialic acid (oligoSia), and polysialic acid (polySia) occur in glycoconjugates. In particular, polySia, a well-known epitope that commonly occurs in neuroinvasive bacteria and vertebrate brains, is one of the most well-known and biologically/neurologically important glycotopes in vertebrates. The biological effects of polySia, especially on neural cell-adhesion molecules, have been well studied, and in-depth knowledge regarding polySia has been accumulated. In addition, the importance of diSia and oligoSia epitopes has been reported. In this chapter, the recent advances in the study of diSia, oligoSia, and polySia residues in glycoproteins in neurology, and their history, definition, occurrence, analytical methods, biosynthesis, and biological functions evaluated by phenotypes of gene-targeted mice, biochemical features, and related diseases are described.